Full Text (PDF 884 KB) Archive Instructions for Authors Contents Alerts Service
Home Submission Copyright Transfer Search


J. Cancer Mol. 4: 37-45, 2008

[Review Article]

Anti-Angiogenic Therapeutic Drugs for Treatment of Human Cancer

Han-Chung Wu, Chia-Ting Huang, and De-Kuan Chang

Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan


One of the proposed benefits of targeted therapies is reduced toxicity and improved quality of life.  The approval of a new broad family of molecularly targeted anticancer drugs represents one of the most significant recent advances in clinical oncology.  The growth of solid tumors is dependent on their capacity to acquire a blood supply.  Much effort has been directed towards the development of drugs that disrupt or normalize this process for cancer therapy.  Some tumors also contain vasculogenic mimicry channels consisting of cancer cells and their extracellular matrix.  In solid tumors, vasculogenic mimicry has been found to be strongly correlated with advanced-stage disease and poor outcome.  In this review article, we summarize the clinical use of small molecules and therapeutic antibodies as angiogenesis inhibitors and their toxic side effects.  We discuss vasculogenic mimicry of solid tumors and describe strategies for identifying putative tumor vascular targets.  We end by discussing the future prospects for the clinical use of vascular targeting in treatment of cancer.

(Keywords: angiogenesis; anti-angiogenic therapy; vasculogenic mimicry; toxicity)


Received 3/30/08; Revised 5/9/08; Accepted 5/12/08.

1. Correspondence: Dr. Han-Chung Wu, Institute of Cellular and Organismic Biology, Academia Sinica, No. 128, Academia Road, Section 2, Nankang, Taipei 11529, Taiwan. Phone: 886-2-27899528. E-mail: hcw0928@gate.sinica.edu.tw

2. Abbreviations: MTD, maximum tolerated dose; LVEF, left ventricular ejection fraction; MAb, monoclonal antibody; CEPs, circulating endothelial progenitor cells; CECs, circulating endothelial cells; AMD, age-related wet macular degeneration; CML, chronic myelogeneous leukemia; TKI, tyrosine kinase inhibitor; RCC, renal cell carcinoma; NSCLC, non-small cell lung cancer; ECM, extracellular matrix; PAS staining, periodic acid schiff staining.


Hyperlink to Full Text [PDF (884 KB)]


Hit Counter